Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules

By M. Mitsunaga, M. Ogawa, N. Kosaka, L. Rosenblum, Peter L. Choyke, Hisataka Kobayashi. Nature Medicine, 2011

951 citations recorded by the source corpus.

Three major modes of cancer therapy (surgery, radiation and chemotherapy) are the mainstay of modern oncologic therapy. To minimize the side effects of these therapies, molecular-targeted cancer therapies, including armed antibody therapy, have been developed with limited success. In this study, we have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was induced immediately after irradiating mAb-IR700–bound target cells with NIR light. We observed in vivo tumor shrinkage after irradiation with NIR light in target cells expressing the epidermal growth factor receptor. The mAb-IR700 conjugates were most effective when bound to the cell membrane and produced no phototoxicity when not bound, suggesting a different mechanism for PIT as compared to conventional photodynamic therapies. Target-selective PIT enables treatment of cancer based on mAb binding to the cell membrane.

Subfields: Biomedical Engineering, Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e8d81a6cb7bd9dc01b80f2f146b065ecf1d4fdd0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Hisataka Kobayashi
2. R. Watanabe
3. Peter L. Choyke

In Cancer Research

1. Peter L. Choyke
2. Hisataka Kobayashi

Citations in the corpus

• Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions (2017, methodology): “The same nanobody was later evaluated for targeted PDT, directly conjugated to IR700 (PS) [297].”
• Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? (2013, methodology): “More recently, another more selective method of killing tumor cells to augment drug delivery, named photo-immunotherapy (PIT), has been described (82).”